Immutep Presents First Clinical Data for IMP761 at Rheumatology Congress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Immutep announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European Alliance of Associations for Rheumatology Congress. Initial clinical findings showed significant and clinically relevant pharmacodynamic activity, including reduction of local inflammatory responses and attenuated T-cell activity compared to placebo. "I am very excited about this first clinical evaluation of IMP761. IMP761 is designed to selectively target overactive T cells linked to chronic inflammation and is now showing clear immunosuppressive effects at dose levels above 0.9 mg/kg in this placebo controlled Phase I study. IMP761 could be positioned to address significant unmet need across multiple autoimmune indications such as rheumatoid arthritis or other T cell driven conditions," said Frederic Triebel, CSO of Immutep.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.374
Low
12.00
Averages
12.00
High
12.00
Current: 0.374
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Immutep is facing a class action lawsuit for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline for participation set for July 6, 2026.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Investors suffered damages when the truth about Immutep's misleading public statements came to light, indicating that the company's disclosures throughout the class period were false and materially misleading.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
See More
Immutep Securities Fraud Class Action Reminder
- Class Action Notice: Bernstein Liebhard LLP reminds investors of Immutep Limited that the deadline to join the securities fraud class action lawsuit against the company is July 6, 2026, requiring investors to file necessary documents by this date to participate in the litigation.
- Investor Eligibility: The lawsuit targets investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, alleging that the company and its executives made materially false statements regarding business operations and financial stability, resulting in artificially inflated ADR prices.
- Potential Losses: Due to these alleged misrepresentations, investors reportedly suffered significant losses when the truth was revealed, indicating that the lawsuit could have substantial financial implications for Immutep shareholders, who need to carefully assess their legal rights.
- Legal Fee Arrangement: Bernstein Liebhard LLP offers contingency fee representation, meaning investors incur no fees or expenses, which may encourage more affected investors to join the lawsuit in pursuit of compensation.
See More
Immutep Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep, alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could undermine the company's reputation and shareholder confidence.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, necessitating an orderly wind-down and patient follow-up, which may adversely affect the company's future product development and market competitiveness.
- Stock Price Collapse: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48, reflecting a pessimistic market outlook on the company's future prospects.
- Legal Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on protecting victims of securities fraud and corporate misconduct, suggesting that this case could lead to broader legal and financial repercussions for Immutep.
See More
Immutep Investors Face Class Action Lawsuit Over TACTI-004 Trial Failures
- Class Action Initiated: The Portnoy Law Firm advises Immutep investors of a class action lawsuit for those who purchased securities between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Trial Failure Impact: Immutep's TACTI-004 Phase III trial was recommended for discontinuation by the Independent Data Monitoring Committee due to futility, resulting in an over 82% drop in the company's stock price on March 13, 2026, indicating a severe loss of investor confidence in the company's future prospects.
- False Statements Allegations: The lawsuit alleges that Immutep made false and misleading statements during the class period, failing to disclose the true status and prospects of the TACTI-004 trial, particularly in light of positive efficacy and safety data from other trials involving efti.
- Legal Consultation Offered: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorneys via phone or email to discuss options for recovering losses, demonstrating the firm's commitment to protecting investor rights.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors about a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Market Reaction: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which could lead to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before the class action is certified to ensure their rights are protected and avoid becoming absent class members.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep Limited, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Immutep's executives made materially false and misleading statements throughout the class period, failing to disclose the true status of the TACTI-004 clinical trial, which may have led to investor misjudgment regarding the company's prospects and impacted its stock price.
- Legal Consequences for Investors: Investors must apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal proceedings in protecting investor rights and interests.
- Law Firm's Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions of dollars for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Immutep is facing a class action lawsuit for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline for participation set for July 6, 2026.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Investors suffered damages when the truth about Immutep's misleading public statements came to light, indicating that the company's disclosures throughout the class period were false and materially misleading.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
See More
Immutep Securities Fraud Class Action Reminder
- Class Action Notice: Bernstein Liebhard LLP reminds investors of Immutep Limited that the deadline to join the securities fraud class action lawsuit against the company is July 6, 2026, requiring investors to file necessary documents by this date to participate in the litigation.
- Investor Eligibility: The lawsuit targets investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, alleging that the company and its executives made materially false statements regarding business operations and financial stability, resulting in artificially inflated ADR prices.
- Potential Losses: Due to these alleged misrepresentations, investors reportedly suffered significant losses when the truth was revealed, indicating that the lawsuit could have substantial financial implications for Immutep shareholders, who need to carefully assess their legal rights.
- Legal Fee Arrangement: Bernstein Liebhard LLP offers contingency fee representation, meaning investors incur no fees or expenses, which may encourage more affected investors to join the lawsuit in pursuit of compensation.
See More
Immutep Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep, alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could undermine the company's reputation and shareholder confidence.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, necessitating an orderly wind-down and patient follow-up, which may adversely affect the company's future product development and market competitiveness.
- Stock Price Collapse: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48, reflecting a pessimistic market outlook on the company's future prospects.
- Legal Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on protecting victims of securities fraud and corporate misconduct, suggesting that this case could lead to broader legal and financial repercussions for Immutep.
See More
Immutep Investors Face Class Action Lawsuit Over TACTI-004 Trial Failures
- Class Action Initiated: The Portnoy Law Firm advises Immutep investors of a class action lawsuit for those who purchased securities between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Trial Failure Impact: Immutep's TACTI-004 Phase III trial was recommended for discontinuation by the Independent Data Monitoring Committee due to futility, resulting in an over 82% drop in the company's stock price on March 13, 2026, indicating a severe loss of investor confidence in the company's future prospects.
- False Statements Allegations: The lawsuit alleges that Immutep made false and misleading statements during the class period, failing to disclose the true status and prospects of the TACTI-004 trial, particularly in light of positive efficacy and safety data from other trials involving efti.
- Legal Consultation Offered: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorneys via phone or email to discuss options for recovering losses, demonstrating the firm's commitment to protecting investor rights.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors about a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Market Reaction: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which could lead to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before the class action is certified to ensure their rights are protected and avoid becoming absent class members.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Immutep Limited, seeking damages for investors who purchased the company's securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Immutep's executives made materially false and misleading statements throughout the class period, failing to disclose the true status of the TACTI-004 clinical trial, which may have led to investor misjudgment regarding the company's prospects and impacted its stock price.
- Legal Consequences for Investors: Investors must apply to be lead plaintiffs by July 6, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal proceedings in protecting investor rights and interests.
- Law Firm's Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions of dollars for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
See More
